Since B38-CAP neither binds to RBD of the Spike nor inhibits viral replication in vitro and in vivo, the ACE2-like enzymatic activity of B38-CAP is crucial for its beneficial effects on lung injury of COVID-19. The gene discussed is ACE2; the disease is COVID-19.